Clinical trial · Interventional
Radiation Therapy for Dupuytren's Contracture Following Non-Surgical Release
A Prospective Clinical Trial of Radiation Therapy for Dupuytren's Contracture Following Surgical and Non-Surgical Release
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to learn about preventing recurrence of Dupuytren's Contracture. The main question it aims to answer are: • Does targeted radiation therapy decrease recurrence of Dupuytren's contracture after treatment with Collagenase Clostridium Histolyticum? Participants will undergo: * Release of Dupuytren's Contracture after Collagenase Clostridium Histolyticum injection * Daily radiation therapy treatment for 5 days followed by 6-8 week rest period and then another course of 5 days of radiation therapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dupuytren Contracture | Palmar Fibromatosis | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiation therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients with Dupuytren's Contacture
- description
- Patients with Dupuytren's Contacture will undergo Collagenase Clostridium Histolyticum injection and release followed by two 5-day courses of radiation therapy separated by 6-8 weeks. They will then be followed for 3 years for recurrence.
- interventionNames
- Radiation: Radiation therapy
Primary outcomes (1)
- measure
- Recurrence of Dupuytren's Contracture
- timeFrame
- one month, 6 months, 12 months, 24 months, and 36 months post-radiation treatment
- description
- Recurrence defined as \> 20 degrees worsening of contracture relative to within 14 days from CCH injection or the need for medical/surgical intervention to correct the new or worsening symptomatic contracture. The investigators will measure the contracture using the table top test in which patients their press hand with best of their ability. We will use a goniometer on dorsal surface of hand while performing table top test to measure PIP and MCP joints.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Age 45 or greater with DC * Extension deficit \>10 degrees * Unable to simultaneously place the affected finger and palm flat on a table. * Women included in the study will be post-menopausal or using contraception, and a pregnancy test will be performed as standard of care. * For patients who are having multiple CCH injections, only the first 2 joints on given hand will be included Exclusion Criteria: * Unsuccessful non-surgical release (\> N/1 disease) * They develop an open wound during CCH * Breast feeding or pregnancy * A chronic muscular, neurologic, or neuromuscular disorder affecting the hands. * Less than the age of 45 * They have previously undergone radiation on the hand in which they plan to get CCH injections * They are pregnant women, impaired adults or prisoners
References
Publications (0)
Data not yet available